INCY: third_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/f2cb59fd-132f-4ba8-bf11-9bd71f04e389/","filing_uuid":"f2cb59fd-132f-4ba8-bf11-9bd71f04e389","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/f2cb59fd-132f-4ba8-bf11-9bd71f04e389/print/","filing_document_content_type":"text/html","income":null,"expenses":"380000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Melissa Banashak","dt_posted":"2026-10-20T12:39:28-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1801 Augustine Cut-Off","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Wilmington","registrant_state":"DE","registrant_zip":"19803","registrant":{"id":401105844,"url":"https://lda.gov/api/v1/registrants/401105844/","house_registrant_id":null,"name":"INCYTE CORPORATION","description":"Biopharmaceutical Company","address_1":"1801 Augustine Cut-Off","address_2":null,"address_3":null,"address_4":null,"city":"Wilmington","state":"DE","state_display":"Delaware","zip":"19803","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MELISSA BANASHAK","contact_telephone":"+1 202-379-8022","dt_updated":"2026-07-28T17:00:17.422432-04:00"},"client":{"id":207939,"url":"https://lda.gov/api/v1/clients/207939/","client_id":12,"name":"INCYTE CORPORATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DE","state_display":"Delaware","country":"US","country_display":"United States of America","ppb_state":"DE","ppb_state_display":"Delaware","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for \"Hidradenitis Suppurativa Awareness Week\" Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140710,"prefix":"ms","prefix_display":"MS.","first_name":"MELISSA","nickname":null,"middle_name":"WIER","last_name":"BANASHAK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148415,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"BARBLAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}